Association of comorbid somatic pathology with fat distribution type and body mass index in men

Author: Iankovskaia S.V.¹, Novikova E.G.², Epanchintseva E.A.³, Pinkhasov B.B.⁴, Selyatitskaya V.G.⁵

Abstract

The purpose of the study was to investigate the effect of overweight, obesity and fat distribution type on the severity of comorbid somatic pathology in men. Material and methods. 216 men, aged from 22 to 78 years, who were patients of therapeutic clinic from 2018 to 2019 years, were observed. Height, body weight, waist (WC) and hip (HC) circumference were measured using standard anthropometric procedures, and then WC/HC and body mass index (BMI) were calculated. Clinical signs of aging were estimated by using the AMS questionnaire. The CIRS was scored from the medical records after hospitalization. Results and discussion. It was shown that overweight and obesity increase the burden of cardiovascular, endocrine and general comorbidity in men. Nevertheless, the burden of cardiovascular pathology did not differ between overweight and obesity men. The contribution of fat distribution type in separate BMI-groups is different. The upper fat distribution type in normal body weight increases the burden of vascular pathology, in overweight – vascular pathology and endocrine system, in obesity – cardiovascular pathology, and general comorbidity in men. Conclusion. Thus, the BMI ≥ 25 kg/m² is associated with an increase burden of cardiovascular, endocrine and general comorbidity and upper fat distribution type increases the burden of vascular pathology in men.

Key words

men, body mass index, fat distribution type, comorbidity, CIRS, cardiovascular pathology, endocrine pathology, AMS questionnaire, aging

References

1. Liu Z., Kuo P.-L., Horvath S., Crimmins E., Ferrucci L., Levine M. A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study. PLoS Med. 2018; 15 (12): 1-20. doi: 10.1371/journal.pmed.1002718

2. Barnett K., Mercer S.W., Norbury M., Watt G., Wyke S., Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012; 380 (9836): 37-43. doi: 10.1016/S0140-6736(12)60240-2

3. Paker N., Buğdaycı D., Gökşenoğlu G., Tekdöş D., İnce N. The reliability of the cumulative illness rating scale and the frequency of comorbidity in stroke. Turk. J. Phys. Med. Rehab. 2017; 63 (1): 9-13. doi: 10.5606/tftrd.2017.66642

4. Pinkhasov B.B., Selyatitskaya V.G.,. Karapetyan A.R,. Lutov Yu.V Association of aging-related obesity and metabolic syndrome in men. Adv. Gerontol. 2016; 6 (3): 224–230.

5. Kachur S., Lavie C.J., Schutter A., Milani R.V., Ventura H.O. Obesity and cardiovascular diseases. Minerva Med. 2017; 108 (3): 212-228. doi: 10.23736/S0026-4806.17.05022-4

6. Mongraw-Chaffin M., Foster M.C., Anderson C.A.M., Burke G.L., Haq N., Kalyani R.R, Ouyang P., Sibley C.T., Tracy R., Woodward M., Vaidya D. Metabolically healthy obesity, transition to metabolic syndrome, and cardiovascular risk. J. Am. Coll. Cardiol. 2018; 71 (17): 1857–1865. doi: 10.1016/j.jacc.2018.02.055

7. Manolopoulos K.N., Karpe F., Frayn K.N. Gluteofemoral body fat as a determinant of metabolic health. Int. J. Obes. 2010; 34 (6): 949–959. doi: 10.1038/ijo.2009.286

8. Piché M.E., Vasan S.K., Hodson L., Karpe F. Relevance of human fat distribution on lipid and lipoprotein metabolism and cardiovascular disease risk. Curr. Opin. Lipidol. 2018; 29 (4): 285–292. doi: 10.1097/mol.0000000000000522

9. Karpe F., Pinnick K.E. Biology of upper-body and lower-body adipose tissue—link to whole-body phenotypes. Nat. Rev. Endocrinol. 2014; 11 (2): 90–100. doi: 10.1038/nrendo.2014.185

10. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 1998; 15 (7): 539–553. doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S

11. Pinkhasov B.B., Selyatitskaya V.G., Karapetyan A.R., Astrakhantseva E.L. Metabolic syndrome in men and women with upper or lower types of body fat distribution. Health. 2012; 4 (12): 1381–1389. doi: 10.4236/health.2012.412A200

12. Daig I., Heinemann L.A., Kim S., Leungwattanakij S., Badia X., Myon E., Moore C., Saad F., Potthoff P., Thai D.M. The Aging Males' Symptoms (AMS) scale: review of its methodological characteristics. Health Qual. Life Outcomes. 2003; 1 (1): 77. doi: 10.1186/1477-7525-1-77

13. Miller M.D., Towers A. A manual of guidelines for scoring the cumulative illness rating scale for geriatrics (CIRS-G). Pittsburgh: University of Pittsburgh School of Medicine, 1991. 30 p.

14. Izmozherova N.V., Popov A.A., Tagiltseva N.V., Andreev A.N., Striukova O.I., Fominykh M.I., Akimova A.V. Assessment of the effect of body weight on the frequency of cardiovascular diseases in menopausal women. Rossiyskiy kardiologicheskiy zhurnal = Russian journal of cardiology. 2006; 58 (2): 62-66. [In Russian].

15. Dennis D., Tampin B., Jacques A., Hebden-Todd T., Carter V., McLintock M., Hurn E., Cooper I. The prevalence of back pain in patients in one Australian tertiary hospital population. Musculoskeletal Care. 2017; 16 (1): 112–117. doi:10.1002/msc.1219

16. Kopp W. How western diet and lifestyle drive the pandemic of obesity and civilization diseases. Diabetes Metab. Syndr. Obes. 2019; 12: 2221-2236. doi: 10.2147/DMSO.S216791

17. Lee D.H., Keum N., Hu F.B., Orav E.J., Rimm E.B., Willett W.C., Giovannucci E.L. Comparison of the association of predicted fat mass, body mass index, and other obesity indicators with type 2 diabetes risk: two large prospective studies in US men and women. Eur. J. Epidemiol. 2018; 33: 1113–1123. doi: 10.1007/s10654-018-0433-5

18. Janssen I. Morbidity and mortality risk associated with an overweight BMI in older men and women. Obesity. 2007; 15 (7): 1827–1840. doi: 10.1038/oby.2007.217

19. Moreno-Viedma V., Amor M., Sarabi A., Bilban M., Staffler G., Zeyda M., Stulnig T.M. Common dysregulated pathways in obese adipose tissue and atherosclerosis. Cardiovasc. Diabetol. 2016; 15 (120): 1-12. doi: 10.1186/s12933-016-0441-2

20. Bersyeneva O.A., Ageeva E.S. Features of etiopathogenesis of metabolic syndrome. Krymskiy zhurnal eksperimental'noy i klinicheskoy meditsiny = Crimea journal of experimental and clinical medicine. 2019; 9 (2): 67-75. [In Russian].

21. Stefan N., Häring H.U., Hu F.B., Schulze M.B. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013; 1 (2): 152-162. doi: 10.1016/S2213-8587(13)70062-7

22. Vasileva O.V., Selyatitskaya V.G. Correlation between obesity and testosterone level, anxiety symptoms, depression and accelerated aging in men. Sibirskiy nauchnyy medtsinskiy zhurnal = Siberian Scientific Medical Journal. 2018; 38 (1): 81-86. [In Russian]. doi: 10.15372/SSMJ20180113

About Authors (Correspondence):

Iankovskaia S.V., е-mail: svetlanaiankovskaia@gmail.com

Full Text

snmzh_4-2020_yankovskaya_i_dr.pdf

Received: 26/08/2020

Accepted: 26/08/2020